Back to Search Start Over

Effect of pre-operative radiation therapy on surgical outcome in retroperitoneal sarcoma.

Authors :
Jo SJ
Park SSW
Yoo GS
Kim KD
Lim SH
Kim J
Kim MJ
Yu JI
Park JB
Lee KW
Source :
Frontiers in surgery [Front Surg] 2023 Jun 12; Vol. 10, pp. 1209698. Date of Electronic Publication: 2023 Jun 12 (Print Publication: 2023).
Publication Year :
2023

Abstract

Background: A high rate of locoregional recurrence is one of the major difficulties in successful treatment of retroperitoneal sarcoma (RPS). Although pre-operative radiation therapy (RT) is considered a potential way to improve local recurrence, concerns about the associated treatment toxicity and risk of peri-operative complications need to be addressed. Hence, this study investigates the safety of pre-operative RT (preRTx) for RPS.<br />Methods: A cohort of 198 patients with RPS who had undergone both surgery and RT was analyzed for peri-operative complications. They were divided into three groups according to the RT scheme: (1) preRTx group, (2) post-operative RT without tissue expander, and (3) post-operative RT with tissue expander.<br />Results: The preRTx was overall well tolerated and did not affect the R2 resection rate, operative time, and severe post-operative complications. However, the preRTx group was associated with higher incidence of post-operative transfusion and admission to intensive care unit ( p  = 0.013 and p  = 0.036, respectively), where preRTx was an independent risk factor only for the post-operative transfusion ( p  = 0.009) in multivariate analysis. The median radiation dose was the highest in preRTx group, although no significant difference was demonstrated in overall survival and local recurrence rate.<br />Conclusion: This study suggests that the preRTx does not add significant post-operative morbidity to the patients with RPS. In addition, radiation dose elevation is achievable with the pre-operative RT. However, a meticulous intra-operative bleeding control is recommended in those patients, and further high-quality trials are warranted to evaluate the long-term oncological outcomes.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (© 2023 Jo, Park, Yoo, Kim, Lim, Kim, Kim, Yu, Park and Lee.)

Details

Language :
English
ISSN :
2296-875X
Volume :
10
Database :
MEDLINE
Journal :
Frontiers in surgery
Publication Type :
Academic Journal
Accession number :
37377670
Full Text :
https://doi.org/10.3389/fsurg.2023.1209698